FPT-CORPORATION
FPT Corporation (FPT), in collaboration with MEDEF International, Business France, the French Chamber of Commerce and Industry (CCIFV), and French Foreign Trade Advisors (CCE), recently organized the France-Vietnam Business Forum in Paris, France. Gathering leading business leaders and tech experts, the event covered topics aiming at accelerating the economic dynamism between Vietnam and France, targeting core industries of both sides, such as aerospace, automotive, manufacturing, energy, and healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527659801/en/
The event was attended by the Vietnamese Ambassador to France, Dinh Toan Thang, Business France, MEDEF International, CCI France Vietnam, French Foreign Trade Advisors, and over 100 high-level government officials, business leaders, and tech experts. (Photo: Business Wire)
“Vietnam is one of France’s main economic partners in Southeast Asia, covering a diverse array of sectors with increasing import of Vietnam’s specialised electronic and textile products. In terms of investment, France is the second largest European (EU) investor in Vietnam, generating 50,000 jobs for this market. In 2023, Business France also supported nine Vietnamese investment projects in France,” said Laurent Saint-Martin, CEO of Business France.
Featuring panelists from global businesses and organizations like NVIDIA, FPT, Egis, Thales, Oerlikon, Valeo, OPmobility, and more, the business forum offered attendees the latest updates in next-gen technology and the national socio-economic outlook. Key topics included the economic attractiveness of France and Vietnam, Vietnam’s momentum as a global digital and investment hub, ethical innovation in artificial intelligence, and smart mobility for a sustainable future.
Throughout the panel discussions, FPT has showcased its broad expertise, industry experience, and extensive global outreach, reaffirming its position as a sustainable transformative enabler with cutting-edge and green technologies.
“Vietnam is emerging as a workforce powerhouse and a global hub for investment and technology, notably in digital transformation and green transition, as well as the advancement of AI and the automotive industry. As the country’s leading corporation, FPT’s strategic directions align with the French government and businesses. We have a robust partnership network, a highly skilled workforce, and a solid global presence to bridge the friendship and cooperation between Vietnam and France’s enterprises,” said Pham Minh Tuan, FPT Executive Vice President and FPT Software CEO.
“FPT is the perfect illustration of what France and Vietnam can achieve together. Their 15 years of presence in France with continuous investments since 2008 have created over 120 jobs and the establishment of three subsidiaries. Their renewed strategic partnership with Airbus in 2021 is also an evident symbol of effective cooperation with the European industrial sector,” Laurent added.
FPT now has over 100 local experts working in France's major cities and 500 offshore professionals in Vietnam, focusing on AI, Big Data, BI, SAP, DevSecOps, Cloud, and AUTOSAR services. Its robust competencies are recognized through strategic partnerships with more than 50 French giants across industries.
As part of the company’s global expansion, FPT has been actively involved in M&A deals to amplify its offshore delivery capabilities and local footprint, notably the recent acquisition of an 80% stake in the French IT consulting firm AOSIS. Last year, its French subsidiary also entered the Top 100 ICT Companies in France, targeting to enter the top 50 by 2028.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527659801/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom